EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Risperidone In Situ Microparticles: A Review in Schizophrenia

Yahiya Y Syed

Drugs · 2025

DOI: 10.1007/s40265-024-02140-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drugs, 2025. Verfasst von Yahiya Y Syed. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com. Hauptthemen laut MEDLINE: Risperidone, Schizophrenia, Antipsychotic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Risperidone in situ microparticles (risperidone ISM®) is a novel long-acting prolonged-release formulation approved in the EU and USA for treating schizophrenia in adults. Once-monthly intramuscular injections of risperidone ISM® provide immediate and sustained therapeutic levels of risperidone, eliminating the need for loading doses or oral supplementation. In the pivotal PRISMA-3 trial in patients with acute schizophrenia exacerbation, risperidone ISM® significantly improved Positive and Negative Syndrome Scale (primary endpoint) and Clinical Global Impression-Severity of Illness (key secondary endpoint) total scores over the 12-week double-blind phase, with improvements observed as early as day 8. Continued treatment sustained efficacy over the 12-month open-label extension phase. Risperidone ISM® also improved social functioning and had a positive impact on health-related quality of life. Patients stable on daily oral risperidone maintained their treatment benefits after switching to monthly risperidone ISM®. Risperidone ISM® was generally well tolerated in clinical trials, with a safety profile consistent with that of oral risperidone. Its fast onset of action, without the need for oral supplementation or loading doses, makes risperidone ISM® a promising long-acting injectable that could enhance treatment adherence. Long-acting injectable (LAI) antipsychotics were developed to improve adherence by maintaining therapeutic levels for weeks or even months. However, some LAIs require oral supplementation or loading doses to ensure adequate plasma concentration at treatment initiation. Risperidone in situ microparticles (risperidone ISM®) is a new LAI approved in the EU and USA for treating schizophrenia in adults. Once-monthly intramuscular injections of risperidone ISM® provide immediate and sustained therapeutic levels without needing oral supplementation or loading doses. In the pivotal PRISMA-3 trial in patients with acute schizophrenia exacerbation, risperidone ISM® significantly reduced symptom severity, with effects seen as early as day 8. Efficacy was sustained over 12 months of continued treatment. Patients stable on oral risperidone maintained benefits after switching to monthly risperidone ISM®. It is generally well tolerated. Therefore, risperidone ISM® is a promising LAI that could enhance treatment adherence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RisperidoneSchizophreniaAntipsychotic AgentsHumansDelayed-Action PreparationsInjections, IntramuscularQuality of Life

Substanzen

RisperidoneAntipsychotic AgentsDelayed-Action Preparations

Autor:innen und Institutionen

  • Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

Zitieren

APA

Syed, Y. Y. (2025). Risperidone In Situ Microparticles: A Review in Schizophrenia. Drugs. https://doi.org/10.1007/s40265-024-02140-2

Vancouver

Syed YY. Risperidone In Situ Microparticles: A Review in Schizophrenia. Drugs. 2025. doi:10.1007/s40265-024-02140-2

BibTeX
@article{Syed2025,
  author = {Syed, Yahiya Y},
  title = {Risperidone In Situ Microparticles: A Review in Schizophrenia},
  journal = {Drugs},
  year = {2025},
  doi = {10.1007/s40265-024-02140-2}
}
Kostenlos starten →